Alzheimer’s Drug Deemed Too Expensive for NHS
Eisai and Biogen’s Alzheimer’s drug Leqembi, also known as lecanemab, has been approved by the UK’s Medicines and Healthcare products Regulatory Agency as the first treatment to slow the progression of the disease. However, patients in Britain’s state-run NHS are unlikely to access it after the National Institute for Health and Care Excellence (NICE) deemed it too costly for widespread use.
BELIEBTE BEITRÄGE
Putin may discuss Ukraine peace deal with Trump
November 22, 2024
Spain’s vice-president Ribera blames floods on climate change
November 22, 2024
Storm lashes northwestern US, killing two people
November 22, 2024
Iceland volcano erupts for tenth time in three years
November 22, 2024
LIVEÜBERTRAGUNG